B. Riley Lowers Agenus (NASDAQ:AGEN) Price Target to $18.00

Agenus (NASDAQ:AGEN) had its price target decreased by analysts at B. Riley from $42.00 to $18.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. B. Riley’s price target would suggest a potential upside of 282.17% from the company’s current price.

Other analysts have also recently issued research reports about the company. Robert W. Baird cut Agenus from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $35.00 to $8.00 in a research report on Friday, July 19th. HC Wainwright cut Agenus from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $40.00 to $9.00 in a research note on Thursday, July 18th. Jefferies Financial Group reissued a “hold” rating and issued a $7.00 price objective (up from $3.00) on shares of Agenus in a report on Friday, July 19th. William Blair downgraded shares of Agenus from an “outperform” rating to a “market perform” rating in a research report on Thursday, July 18th. Finally, StockNews.com lowered Agenus from a “hold” rating to a “sell” rating in a report on Monday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, Agenus has an average rating of “Hold” and a consensus target price of $10.50.

Agenus Price Performance

Shares of NASDAQ AGEN opened at $4.71 on Wednesday. The business has a 50-day moving average of $11.84 and a two-hundred day moving average of $11.94. The company has a market capitalization of $98.91 million, a price-to-earnings ratio of -0.37 and a beta of 1.33. Agenus has a 1 year low of $4.68 and a 1 year high of $32.00.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The business had revenue of $23.51 million for the quarter, compared to the consensus estimate of $64.73 million. During the same quarter in the prior year, the firm posted ($4.00) earnings per share. As a group, equities research analysts expect that Agenus will post -10.73 earnings per share for the current year.

Hedge Funds Weigh In On Agenus

A number of large investors have recently bought and sold shares of the company. Blair William & Co. IL acquired a new position in shares of Agenus during the second quarter worth about $441,000. Ovata Capital Management Ltd acquired a new position in Agenus during the 2nd quarter worth approximately $670,000. RPO LLC acquired a new position in Agenus during the 4th quarter worth approximately $43,000. Ables Iannone Moore & Associates Inc. purchased a new position in shares of Agenus during the 4th quarter worth approximately $65,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Agenus in the 2nd quarter valued at approximately $1,921,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.